A type of intravenous colloid used in the prevention or treatment of shock associated with reduction in effective circulating blood volume due to hemorrhage, loss of plasma (burns, peritonitis, pancreatitis, crush injuries), or loss of water and electrolytes from persistent vomiting and diarrhea. Haemaccel contains degraded gelatin.
Haemaccel (also marketed as Emagel in Italy and Solucel in Venezuela) was originally brought to market by Sanofi-Aventis, and later acquired by Nicholas_Piramal.
References
 |
This medical treatment article is a stub. You can help Wikipedia by expanding it. |
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
This entry is from Wikipedia, the leading user-contributed encyclopedia. It may not have been reviewed by professional editors (see full disclaimer)
